Ocular Effects of Yogic Breathing (Nadi Shodhan Pranayam) on Diabetic Macular Edema Patients Receiving Intravitreal Anti-Vascular Endothelium Growth Factor Injection

Ocular Effects of Yogic Breathing (Nadi Shodhan Pranayam) on Diabetic Macular Edema Patients Receiving Intravitreal Anti-Vascular Endothelium Growth Factor Injection: A Prospective Randomized Pilot Study - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105931

Enrollment

Registered

2026-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E113- Type 2 diabetes mellitus with ophthalmic complications

Interventions

Intervention1: NADI SHODHAN PRANAYAM: (NADI SHODHAN PRANAYAM) 1. Sit in a calm, quiet, airy place in an easy and steady posture with the head, neck, and trunk erect and in a straight line. The body sh

the index and middle fingers should be folded so that the right thumb can be used to close the right nostril and the ring finger used to close the left nostril. 3. With the right nostril closed, exhal

Eligibility

Inclusion criteria

Inclusion criteria: Patients of diabetes mellitus type 2 Age group 40-70 years All patients of non proliferative diabetic retinopathy (NPDR) with diabetic macular edema Patient willing to give written informed consent and willing to participate in study.

Exclusion criteria

Exclusion criteria: Any ocular pathology obscuring the Optical Coherence Tomography (OCT) imaging Presence of any other ocular disease or posterior segment disorder like glaucoma, uveitis, Age Related Macular Disease or any vascular occlusive disease affecting macula. Treated with laser photocoagulation Received intravitreal antiVEGF injection in preceding 6 months Patients with poorly controlled blood sugar levels Patients who do not follow up after at least 1 month following intravitreal antiVEGF injection Not able to perform YBP in YBP group Any lung disease like chronic obstructive pulmonary disease (COPD), asthma Patient with chronic kidney disease Any intraocular surgery in past 1 year Patients with past history of posterior segment surgeries or any history of past ocular trauma. Unwilling and uncooperative patient

Design outcomes

Primary

Measure	Time frame
1.To compare change between central subfield thickenss (CST) in YBP and Control groups, pre and post intravitreal antiVEGF injection with or without YBP respectively at baseline and 4 weeksTimepoint: 1.To compare change between central subfield thickenss (CST) in YBP and Control groups, pre and post intravitreal antiVEGF injection with or without YBP respectively at baseline and 4 weeks	—

Secondary

Measure	Time frame
To assess BCVA in YBP and Control groups, pre and post intravitreal antiVEGF injection with or without YBP respectively.Timepoint: from baseline to 6 weeks post intravitreal anti-vascular endothelium growth factor injection	—

Countries

India

Contacts

Public ContactDEEPA KUMARI

AIIMS, RISHIKESH

deepa981998@gmail.com07588403516

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026